Viacyte company information, Employees & Contact Information

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes Bain Capital

Exciting Advancements in Cell Replacement Therapy Breakthrough T1D Canada

ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes PR Newswire

Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes Nature

Vertex absorbs ViaCyte and its stem cell-based diabetes treatment for $320M, clearing out competition Fierce Biotech

Vertex’s Viacyte Backs Out of CRISPR Diabetes Deal BioSpace

Viacyte Receives Funding to Continue Developing Beta Cell Therapies Breakthrough T1D

ViaCyte and CRISPR Introduce New Stem Cell Therapy for Type 1 Diabetes Making Sense of Diabetes

ViaCyte And W. L. Gore & Associates Announce Collaborative Research Agreement To Develop Novel Implantable Delivery Technologies For Cell Therapies Med Device Online

CRISPR, ViaCyte dose first subject in Phase I diabetes trial Clinical Trials Arena

Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte for $320M Drug Delivery Business

ViaCyte to build on POC for diabetes cell therapy with durability data BioCentury

ViaCyte Announces $10 Million in Financing PR Newswire

Exciting news: stem cell-based treatments producing insulin in participants with type 1 diabetes Breakthrough T1D Canada

Vertex cuts ties to CRISPR Therapeutics’ type 1 diabetes stem cell therapy Fierce Biotech

Type 1 Diabetes Cures in Spotlight with Vertex Deal Making Sense of Diabetes

ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes PR Newswire

ViaCyte bags $80M to trial diabetes stem cell therapies Fierce Biotech

ViaCyte To Participate In World Medical Innovation Forum Panel On Future Of Cell Therapy For Type 1 Diabetes PR Newswire

ViaCyte Appoints Sandra E. Poole to Board of Directors PR Newswire

Cell delivery systems: Toward the next generation of cell therapies for type 1 diabetes Wiley Online Library

CRISPR and ViaCyte Dose First Patient in Historic Type 1 Diabetes Trial BioSpace

From pluripotent stem cells to bioengineered islets: A challenging journey to diabetes treatment ScienceDirect.com

Vertex acquires another maker of potentially curative diabetes treatments BioPharma Dive

Vertex to Acquire ViaCyte for $320M, Growing Diabetes Cell Therapy Pipeline Genetic Engineering and Biotechnology News

Vertex signs agreement to acquire ViaCyte for $320m Pharmaceutical Technology

Vertex to buy ViaCyte to boost development of type 1 diabetes cell therapy FirstWord Pharma

Vertex boosting diabetes cell therapy with ViaCyte buy - BioProcess Insider BioProcess International

Functional Beta Cell Mass from Device-Encapsulated hESC-Derived Pancreatic Endoderm Achieving Metabolic Control ScienceDirect.com

Diabetes space continues to run hot with Vertex/ViaCyte deal Medical Marketing and Media

First Patient Dosed with VCTX210, a Cell Therapy for Type 1 Diabetes: Mary Ann Liebert, Inc.

Advances and challenges of the cell-based therapies among diabetic patients Journal of Translational Medicine

ViaCyte’s Sweet Three-Pronged Attack against Type 1 Diabetes Genetic Engineering and Biotechnology News

Sweet Spot: CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for Type 1 Diabetes Genetic Engineering and Biotechnology News

Johnson & Johnson, ViaCyte testing possible diabetes cure The Florida Times-Union

Vertex Pharmaceuticals announces they have acquired ViaCyte Breakthrough T1D Canada

ViaCyte taps Gore to develop delivery devices for diabetes cell therapy Fierce Biotech

ViaCyte Acquires Rights to BetaLogics Assets for Stem Cell-Derived Approaches to Type 1 Diabetes BioInformant

Gore adds $10m to ViaCyte investment Drug Delivery Business

CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy BioSpace

ViaCyte enters partnership with Janssen - Global Venturing

Novocell becomes ViaCyte - Global Venturing